1-甲基-4-吡啶-3-基哌啶-4-醇 | 75446-42-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-甲基-4-吡啶-3-基哌啶-4-醇
• 英文名称: 4-hydroxy-1-methyl-4-(3-pyridyl)piperidine
• 英文别名: 4-Piperidinol, 1-methyl-4-(3-pyridinyl)-；1-methyl-4-pyridin-3-ylpiperidin-4-ol
• CAS: 75446-42-3
• 化学式: C₁₁H₁₆N₂O
• 分子量: 192.261
• InChiKey: GHHFIXSVTXTKTH-UHFFFAOYSA-N

物化性质

• 沸点：
  345.1±42.0 °C(Predicted)
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-甲基-4-吡啶-3-基哌啶-4-醇 在 硫酸 作用下， 反应 5.0h， 以100%的产率得到1-methyl-4-(3-pyridinyl)-1,2,5,6-tetrahydropyridine
  参考文献：
  名称：

  Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines

  摘要：

  A series of pyridinyltetrahydropyridine derivatives was synthesized and evaluated as adrenoceptor and tetrabenazine antagonists. 4-(3-Fluoro-2-pyridinyl)-1,2,5,6-tetrahydropyridine proved to be the most potent and selective alpha 2-adrenoceptor antagonist of the series as measured in vitro by displacement of [3H]clonidine and [3H]prazosin from membrane binding sites of calf cerebral cortex and by antagonism of the effects of clonidine and methoxamine in the rat isolated, field-stimulated vas deferens. In addition, this compound, and the corresponding desfluoro derivative, blocked tetrabenazine-induced ptosis in the mouse.

  DOI：

  10.1021/jm00375a017
• 作为产物：
  描述：

  3-溴吡啶 在 390 作用下， 以 乙醚 为溶剂， 反应 2.0h， 生成 1-甲基-4-吡啶-3-基哌啶-4-醇
  参考文献：
  名称：

  合成和单胺氧化酶B催化C-4杂芳族取代的1,2,3,6-四氢吡啶衍生物的氧化。

  摘要：

  已经提出胺的单胺氧化酶B（MAO-B）催化的氧化通过极性途径，初始的单电子转移途径和初始的氢原子转移途径进行。以前对选定的N-环丙基-4-取代的1,2,3,6-四氢吡啶衍生物的研究结果使我们考虑了这些环状叔烯丙胺的机理，这种机理不一定像最初所要求的那样涉及胺基自由基阳离子。单电子转移步骤。本文进行了总结性研究，以进一步探索确定MAO-B底物和/或各种1,4-二取代四氢吡啶衍生物的灭活剂性质的结构特征。我们在这里报告了我们对1-甲基-和1-环丙基-1,2,3的合成和MAO-B催化氧化的研究结果，在C-4带有多个杂芳族基团的6-四氢吡啶衍生物。所有的N-环丙基四氢吡啶类似物都是MAO-B的时间和浓度依赖性抑制剂，而所有的N-甲基四氢吡啶类似物和N-环丙基-4-（1-甲基-2-吡啶基）四氢吡啶类似物都是底物。底物性能（Kcat / KM）覆盖范围为6至1800 min-1 mM-1，而可得到Kinact

  DOI：

  10.1021/tx960063o

文献信息

• Electronic study of receptor binding of analgesic aryl moiety II: Prodine analogs
  作者：Khalid Sabih A. Razzak、Khawla A. Hamid

  DOI：10.1002/jps.2600690713

  日期：1980.7

  Analogs of the prodine analgesics were prepared and tested for analgesic activity. A good correlation seems to exist between the energy level of the highest occupied molecular orbital and biological activity. The energy level of the highest occupied molecular orbital of the aryl moiety of these analogs may permit a charge transfer interaction between the aryl groups of the analgesic molecules and their

  制备了脯氨酸镇痛药的类似物并测试了镇痛活性。占据最高分子轨道的能级与生物活性之间似乎存在良好的相关性。这些类似物的芳基部分的最高占据分子轨道的能级可以允许止痛剂分子的芳基与其受体之间的电荷转移相互作用，其中芳基充当电荷供体。
• Modulators of CB1 Receptors
  申请人：Cooper Martin

  公开号：US20100144701A1

  公开（公告）日：2010-06-10

  Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh gain, treatment of diseases and conditions directly or indirectly associated with obesity and overweight: wherein A 1 is hydrogen, —COOH,or tetrazolyl; p and q are independently 0 or 1; A3 is phenyl or cycloalkyl, either of which is optionally substituted with R 4 and/or R 5 ; R 4 and R 5 are independently —R 9 , —CN, —F, —Cl, —Br, —OR 9 , —NR 7 R 8 , —NR 7 COR 6 , —NR 7 SO 2 R 6 , —COR 6 , —SR 9 , —SOR 9 , or —SO 2 R 6 ; R 6 is C 1 -C 4 alkyl, cycloalkyl, —CF 3 or —NR 7 R 8 ; R 7 and R 8 are independently hydrogen, C 1 -C 4 alkyl or cycloalkyl; R 9 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkoxy(C 1 -C 4 alkyl)-, cycloalkyl, or fully or partially fluorinated C 1 -C 4 alkyl; R 1 (i) a bond; (ii) a divalent radical of formula —(CH 2 ) a B 1 (CH 2 ) b wherein a and b are independently O, 1, 2 or 3 provided that a+b is 1, 2 or 3, and B 1 is —CO—, —O—, —S—, —SO—, —SO 2 —, —CH 2 —, —CHCH 3 —, —CHOH— or —NR 7 —; or (iii) a divalent radical selected from —C(R 10 )(R 11 )—*, —C(R 10 )(R 11 )—O—*, —C(R 10 )(R 11 )CH 2 —*, —C(R 10 )(R 11 )CH 2 —O—*, —CH 2 C(R 10 )(R 11 )—*, —CH 2 C(R 10 )(R 11 )—O—*, —CH 2 —O—C(R 10 )(R 11 )—* and —C(R 10 )(R 11 )—O—CH 2 —*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; Z is as defined in the specification; R 10 is hydrogen and R 11 is (C 1 -C 3 )alkyl or —OH; or R 10 and R 11 are both (C 1 -C 3 )alkyl; or R 10 and R 11 taken together with the carbon atom to which they are attached form a (C 3 -C 5 )cycloalkyl ring.

  式(I)的化合物抑制CB1受体的正常信号活动，因此可用于治疗由CB1受体信号活动介导的疾病或症状，例如肥胖和超重的治疗，预防体重增加，直接或间接与肥胖和超重相关的疾病和症状的治疗：其中A1是氢，-COOH或四唑基；p和q独立地为0或1；A3是苯基或环烷基，其中任一可选地用R4和/或R5取代；R4和R5独立地为-R9，-CN，-F，-Cl，-Br，-OR9，-NR7R8，-NR7COR6，-NR7SO2R6，-COR6，-SR9，-SOR9或-SO2R6；R6是C1-C4烷基，环烷基，-CF3或-NR7R8；R7和R8独立地为氢，C1-C4烷基或环烷基；R9为氢，C1-C4烷基，C1-C4烷氧基，C1-C4烷氧基（C1-C4烷基）-，环烷基或完全或部分氟化的C1-C4烷基；R1(i)为键；（ii）为式-（CH2）aB1（CH2）b的二价基团，其中a和b独立地为O，1，2或3，前提是a+b为1，2或3，B1为-CO-，-O-，-S-，-SO-，-SO2-，-CH2-，-CHCH3-，-CHOH-或-NR7-；或（iii）为从-C（R10）（R11）- *，-C（R10）（R11）-O- *，-C（R10）（R11）CH2- *，-C（R10）（R11）CH2- O- *，-CH2C（R10）（R11）- *，-CH2C（R10）（R11）-O- *，-CH2-O-C（R10）（R11）- *和-C（R10）（R11）-O-CH2- *中选择的二价基团，其中由星号表示的键连接到吡唑环；Z如规范中所定义；R10为氢，R11为（C1-C3）烷基或-OH；或R10和R11均为（C1-C3）烷基；或R10和R11与它们连接的碳原子一起形成（C3-C5）环烷基环。
• TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20160185780A1

  公开（公告）日：2016-06-30

  Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

  本文描述了化学式为0、化学式I和化学式II的化合物以及作为Janus激酶抑制剂的使用方法。
• [EN] COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS<br/>[FR] COMPOSÉS ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS, DÉGÉNÉRATIFS ET MÉTABOLIQUES
  申请人：SCRIPPS RES INSTITUTE THE

  公开号：WO2022125989A1

  公开（公告）日：2022-06-16

  Provided are, inter alia, compounds having a structure of Formula (X), or a pharmaceutically acceptable salt thereof composition including the same and methods of use. Ring A, L1, L2, W, R2A, R2B, and R10are as described herein.

  提供的是具有公式（X）结构的化合物，或其药学上可接受的盐，包括该化合物的组合物以及使用方法。环A、L1、L2、W、R2A、R2B和R10的描述如本文所述。
• Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10441581B2

  公开（公告）日：2019-10-15

  Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供的是式 I 的化合物： 或其药学上可接受的盐或溶液，其中 A、B、X1、X2、X3、X4、环 D、E、Ra、Rb、n 和 m 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可用 RET 激酶抑制剂治疗的疾病，包括 RET 相关疾病和失调。